WuXi Biologics
Offering End-to-End Solutions
Plasmid DNA
|
WuXi Biologics’ Platform Process
|
Research Grade
|
High Quality (HQ)
|
cGMP
|
|
WuXi Biologics platform production process
|
√
|
√
|
√
|
|
Certificate of Analysis (CoA)
|
√
|
√
|
√
|
|
E. coli master and working cell bank generation
|
|
√
|
√
|
|
Controlled facility and environment
|
|
√
|
√
|
|
Manufacturing summary report
|
|
√
|
√
|
|
BSE/TSE statement
|
|
√
|
√
|
|
QA oversight
|
|
√ (critical steps only) |
√
|
|
E. coli strain screening and process development
|
|
|
√
|
|
Product specific batch records
|
|
|
√
|
|
Validated facility/equipment/methods
|
|
√
|
|
WuXi Biologics’ Platform Process
|
Research Grade
|
High Quality (HQ)
|
cGMP
|
|
Lead time for project kickoff (upon receipt of order) |
<2 weeks
|
<4 weeks
|
<4 weeks
|
|
Manufacturing production period (starting from strain transformation) |
1-2 weeks
|
16-20 weeks
|
24-26 weeks
|
|
Progress update
|
Weekly
|
Biweekly
|
Biweekly
|
| Dedicated project manager |
Yes
|
Yes
|
Yes
|
| Certificated of Analysis (CoA) |
√
|
√
|
√
|
| Manufacturing summary report |
√
|
√
|
|
| Manufacturing batch records |
√
|
||
| cGMP compliance statement |
√
|
- Strain: Optimal for propagating retroviral/lentiviral genes
- Scale: 10-300L fermenter
- pDNA titer: 1300 mg/L and above (industry average 300-1000 mg/L)
- Yield: 45–55% (industry average 30-40%)
- Supercoiled (sc) pDNA ratio: > 96% (industry average >90%)
- High product quality and low impurities
|
WuXi Biologics Platform
|
Industry Benchmark | |
|
Upstream Fermentation Process
|
||
| Working volume. |
5 L and above
|
5-500 L
|
| Harvest OD600 |
70-150
|
55-120
|
| Plasmid titer |
1000 mg/L and above
|
350-1000 mg/L
|
|
Downstream Purification Process
|
||
| (Weak anion exchange + MMC) |
45-55%
|
30-40%
|
|
Key Product Quality Attributes
|
||
| sc pDNA ratio |
>96%
|
>80%
|
| Endotoxin |
<2 EU/mg pDNA
|
<40 EU/mg pDNA
|
| Host cell DNA-removed |
>99.5%
|
>99%
|
| Host cell protein-removed |
>99%
|
>99%
|
| RNA-removed |
>99%
|
>99%
|